RxDoctor Payments Data

Maliha Shakil, MD

Internal Medicine · Spring, TXNPI 1619327004

Payments from drug & device makers

$1,068in general payments, 2019–2025

Across 52 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$250
  • Lilly USA, LLC$158
  • Johnson & Johnson$102
  • Pfizer$95
  • GSK$80
  • Dexcom, Inc.$67
  • plus $317 from 11 others

What the payments were for

  • Food & beverage$1,068100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,068 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$82,951
Medicare patients
199
Services billed
2,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin87$115,447
OzempicSemaglutide57$72,400
MounjaroTirzepatide57$57,039
EliquisApixaban40$37,766
RybelsusSemaglutide24$36,532
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$28,753
TrulicityDulaglutide22$23,506
FarxigaDapagliflozin Propanediol19$22,900
LinzessLinaclotide15$16,114
BrilintaTicagrelor11$5,577
ArexvyRsvpref3 Antigen/As01e/Pf11$3,560
Levothyroxine Sodium293$3,147
FingolimodFingolimod Hcl12$2,529
Gabapentin147$2,008
Atorvastatin Calcium298$1,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$23$115,44787 claims
Novo NordiskOzempic, Rybelsus$47$108,93281 claims
Lilly USA, LLCMounjaro, Trulicity$158$80,54579 claims
PfizerEliquis$95$37,76640 claims
GSKTrelegy Ellipta, Arexvy$80$32,31350 claims
AstraZenecaFarxiga, Brilinta$250$28,47730 claims
AbbVieLinzess, Synthroid$58$17,28232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →